Literature DB >> 18257133

Determination of risperidone in human plasma by HPLC-MS/MS and its application to a pharmacokinetic study in Chinese volunteers.

Ming-zhu Huang1, Jian-zhong Shentu, Jun-chun Chen, Jian Liu, Hui-li Zhou.   

Abstract

This study presents a rapid, specific and sensitive liquid chromatography/tandem mass spectrometry (LC-MS/MS) assay for determination of risperidone (RIS) in human serum using paroxetine as an internal standard (IS). An Alltima-C18 column (2.1 mmx100 mm, 3 microm) and a mobile phase consisting of 0.1% formic acid-acetonitrile (40:60, v/v) were used for separation. The analysis was performed by selected reaction monitoring (SRM) method, and the peak area of the m/z 411.3-->191.1 transition for RIS was measured versus that of the m/z 330.1-->192.1 transition for IS to generate the standard curves. The assay linearity of RIS was confirmed over the range 0.25 approximately 50.00 ng/ml and the limit of quantitation was 0.05 ng/ml. The linear range corresponds well with the serum concentrations of the analytes obtained in clinical pharmacokinetic studies. Intraday and interday relative standard deviations were 1.85% approximately 9.09% and 1.56% approximately 4.38%, respectively. The recovery of RIS from serum was in the range of 70.20% approximately 84.50%. The method was successfully applied to investigate the bioequivalence between two kinds of tablets (test versus reference products) in 18 healthy male Chinese volunteers. The result suggests that two formulations are bioequivalent.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18257133      PMCID: PMC2225493          DOI: 10.1631/jzus.B0710439

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  15 in total

1.  Validated method for the determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography-tandem mass spectrometry.

Authors:  B M M Remmerie; L L A Sips; R de Vries; J de Jong; A M Schothuis; E W J Hooijschuur; N C van de Merbel
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2003-01-15       Impact factor: 3.205

2.  Determination of risperidone and enantiomers of 9-hydroxyrisperidone in plasma by LC-MS/MS.

Authors:  B Cabovska; S L Cox; A A Vinks
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-02-15       Impact factor: 3.205

3.  Electrospray ionisation-mass spectrometric characterisation of selected anti-psychotic drugs and their detection and determination in human hair samples by liquid chromatography-tandem mass spectrometry.

Authors:  S McClean; E J O'Kane; W F Smyth
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2000-04-14

4.  Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors.

Authors:  A E Balant-Gorgia; M Gex-Fabry; C Genet; L P Balant
Journal:  Ther Drug Monit       Date:  1999-02       Impact factor: 3.681

5.  Simultaneous determination of risperidone and 9-hydroxyrisperidone in plasma by liquid chromatography/electrospray tandem mass spectrometry.

Authors:  M Aravagiri; S R Marder
Journal:  J Mass Spectrom       Date:  2000-06       Impact factor: 1.982

6.  A high-performance liquid chromatographic-atmospheric pressure chemical ionization-tandem mass spectrometric method for determination of risperidone and 9-hydroxyrisperidone in human plasma.

Authors:  David E Moody; John D Laycock; Wei Huang; Rodger L Foltz
Journal:  J Anal Toxicol       Date:  2004-09       Impact factor: 3.367

7.  Turbulent flow and ternary column-switching on-line clean-up system for high-throughput quantification of risperidone and its main metabolite in plasma by LC-MS/MS: application to a bioequivalence study.

Authors:  Constantinos Kousoulos; Yannis Dotsikas; Yannis L Loukas
Journal:  Talanta       Date:  2006-12-19       Impact factor: 6.057

8.  Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects.

Authors:  M L Huang; A Van Peer; R Woestenborghs; R De Coster; J Heykants; A A Jansen; Z Zylicz; H W Visscher; J H Jonkman
Journal:  Clin Pharmacol Ther       Date:  1993-09       Impact factor: 6.875

9.  Absorption, metabolism, and excretion of risperidone in humans.

Authors:  G Mannens; M L Huang; W Meuldermans; J Hendrickx; R Woestenborghs; J Heykants
Journal:  Drug Metab Dispos       Date:  1993 Nov-Dec       Impact factor: 3.922

10.  Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection.

Authors:  M Aravagiri; S R Marder; D Wirshing; W C Wirshing
Journal:  Pharmacopsychiatry       Date:  1998-05       Impact factor: 5.788

View more
  6 in total

1.  Relative bioavailability and pharmacokinetic comparison of two different enteric formulations of omeprazole.

Authors:  Jian Liu; Jian-zhong Shentu; Li-hua Wu; Jing Dou; Qi-yang Xu; Hui-li Zhou; Guo-lan Wu; Ming-zhu Huang; Xing-jiang Hu; Jun-chun Chen
Journal:  J Zhejiang Univ Sci B       Date:  2012-05       Impact factor: 3.066

2.  Development and Validation of Liquid Chromatography/Tandem Mass Spectrometry Analysis for Therapeutic Drug Monitoring of Risperidone and 9-Hydroxyrisperidone in Pediatric Patients with Autism Spectrum Disorders.

Authors:  Natchaya Vanwong; Santirat Prommas; Apichaya Puangpetch; Yaowaluck Hongkaew; Nopadol Nuntamool; Chalitpol Na Nakorn; Nattawat Ngamsamut; Penkhae Limsila; Chonlaphat Sukasem
Journal:  J Clin Lab Anal       Date:  2016-06-26       Impact factor: 2.352

3.  Effects of atypical (risperidone) and typical (haloperidol) antipsychotic agents on astroglial functions.

Authors:  André Quincozes-Santos; Larissa Daniele Bobermin; Rafaela Pestana Leques Tonial; Victorio Bambini-Junior; Rudimar Riesgo; Carmem Gottfried
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-12-30       Impact factor: 5.270

4.  Stability indicating HPLC determination of risperidone in bulk drug and pharmaceutical formulations.

Authors:  Zarna R Dedania; Ronak R Dedania; Navin R Sheth; Jigar B Patel; Bhavna Patel
Journal:  Int J Anal Chem       Date:  2011-10-10       Impact factor: 1.885

5.  Spectrophotometric estimation of risperidone in tablets.

Authors:  B K Jayanna; T D Devaraj; K P Roopa; G Nagendrappa; H R Arun Kumar; N Gowda
Journal:  Indian J Pharm Sci       Date:  2014-09       Impact factor: 0.975

6.  New Modified UPLC/Tandem Mass Spectrometry Method for Determination of Risperidone and Its Active Metabolite 9-Hydroxyrisperidone in Plasma: Application to Dose-Dependent Pharmacokinetic Study in Sprague-Dawley Rats.

Authors:  Essam Ezzeldin; Marwa Tammam; Nisreen F Abo Talib
Journal:  Int J Anal Chem       Date:  2017-05-03       Impact factor: 1.885

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.